The influence of gastrointestinal parasitism on fecal elimination of doramectin, in lambs.

Rubén Pérez, Cristina Palma, Ignacio Cabezas, Luis Rubilar, Margarita Arboix, Rubén Pérez, Cristina Palma, Ignacio Cabezas, Luis Rubilar, Margarita Arboix

Index: Ecotoxicol. Environ. Saf. 73(8) , 2017-21, (2010)

Full Text: HTML

Abstract

A study was done to investigate the effect of parasitism on patterns of doramectin (DRM) fecal elimination in lambs. Fourteen Suffolk Down parasitized lambs (26.9 ± 1.5 kg body weight: bw) were purposely selected for the study. Seven pairs of lambs were allocated into two experimental groups. Group I (non-parasitized) was pre-treated with 3 repeated administrations of 5mg/kg bw of fenbendazole to maintain a non-parasitized condition. In Group II (parasitized), the lambs did not receive any anthelmintic treatment. After 85 d of the pre-treatment period, both groups were treated with a subcutaneous injection of 200 μg/kg bw of DRM. Fecal samples were collected at different times between -85 d before and 60 d after the DRM treatment, for both parasitological and chromatographic analysis. Samples were analyzed by high-performance liquid chromatography (HPLC) with fluorescence detection. Data of DRM concentrations were expressed as wet weight. A non-linear pharmacokinetic analysis was performed and results were compared using the Mann Whitney test. Fecal maximum concentrations (C(max)) of DRM were 1.37 ± 0.19 μg/g (parasitized group) and 0.86 ± 0.15 μg/g (non-parasitized group) observed at the time of the maximum concentration (T(max)) of 2.1 ± 0.4 and 3.1 ± 0.3d, respectively. Differences in C(max) values were significant (P<0.05). The accumulated elimination of DRM in feces, expressed as the percentage of DRM total dose, was 67.1% in the parasitized group, whereas in the non-parasitized group it was 56.5%. Our results showed that gastrointestinal parasitic diseases can modify the patterns of DRM fecal elimination, when the drug is administered by subcutaneous route in lambs.Copyright © 2010 Elsevier Inc. All rights reserved.